<table>
<thead>
<tr>
<th>Title</th>
<th>Controlled-release nanoencapsulating microcapsules to combat inflammatory diseases</th>
</tr>
</thead>
<tbody>
<tr>
<td>Author(s)</td>
<td>Baek, Jong-Suep; Yeo, Eng Wan; Lee, Yin Hao; Tan, Nguan Soon; Loo, Say Chye Joachim</td>
</tr>
<tr>
<td>Date</td>
<td>2017</td>
</tr>
<tr>
<td>URL</td>
<td><a href="http://hdl.handle.net/10220/43653">http://hdl.handle.net/10220/43653</a></td>
</tr>
<tr>
<td>Rights</td>
<td>© 2017 Baek et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at <a href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</a> and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License (<a href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</a>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (<a href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</a>).</td>
</tr>
</tbody>
</table>
Controlled-release nanoencapsulating microcapsules to combat inflammatory diseases

Jong-Suep Baek¹
Eng Wan Yeo¹
Yin Hao Lee²
Ngan Soon Tan³
Say Chye Joachim Loo¹,³
¹School of Materials Science and Engineering, Nanyang Technological University, Singapore; ²School of Biological Sciences, Nanyang Technological University, Singapore; ³Singapore Centre on Environmental Life Sciences Engineering (SCELSE), Nanyang Technological University, Singapore

Abstract: The World Health Organization (WHO) has reported that globally 235 million people suffer from chronic and other inflammatory diseases. The short half-lives of nonsteroidal anti-inflammatory drugs (NSAIDs) and their notoriety in causing gastrointestinal discomforts, warrants these drugs to be released in a controlled and sustained manner. Although polymeric particles have been widely used for drug delivery, there are few reports that showcase their ability in encapsulating and sustaining the release of NSAIDs. In this paper, polymeric nanoencapsulating microcapsules loaded with NSAIDs were fabricated using solid/water/oil/water emulsion solvent evaporation method. Two NSAIDs, ibuprofen and naproxen, were first pre-loaded into nanoparticles and then encapsulated into a larger hollow microcapsule that contained the third NSAID, celecoxib. A high encapsulation efficiency (%) of these NSAIDs was achieved and a sustained release (up to 30 days) of these drugs in phosphate-buffered saline was observed. Then, a gastrointestinal drug – cimetidine (CIM) – was co-loaded with the NSAIDs. This floating delivery system exhibited excellent buoyancy (~88% up to 24 h) in simulated gastric fluid. It also allowed a sequential release of the drugs, whereby an immediate release of CIM followed by NSAIDs was observed. Drug release of the NSAIDs observed Fickian diffusion mechanism, whereas CIM observed non-Fickian diffusion. Therefore, this delivery system is a promising platform to control the delivery of NSAIDs to combat inflammatory diseases, thereby protecting against possible gastrointestinal side effects that may arise from the overuse of NSAIDs.

Keywords: NSAIDs, multi-drug encapsulation, sequential release, floating oral drug delivery, injectable system, oral delivery systems, diffusion, emulsion, sustained release

Introduction

Inflammation is an innate immune response to noxious stimuli, damaged cells, irritants, and microorganisms. Inflammation, as a natural biological mechanism, aids in eliminating the cause of tissue injury and healing the damaged tissues. Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly prescribed to treat inflammation and the pain associated with it.¹ NSAIDs act on the cyclooxygenase (COX) family of enzymes and inhibit the conversion of arachidonic acid to prostaglandins and thromboxanes.²³ The COX-1 enzyme is expressed in most tissues and helps to regulate hemodynamics and maintain gut integrity. However, COX-2 is found in inflamed sites and mediates pain associated with it.³ The World Health Organization (WHO) has reported that globally 235 million people suffer from chronic and other inflammatory diseases. Therefore, the global market for anti-inflammatory therapeutics is expected to grow rapidly at a compound annual growth rate (CAGR) of 5.9% and is estimated to worth USD 106.1 billion by 2020.⁶

Among the NSAIDs, ibuprofen (IBU; 2-(4-(2-Methylpropyl)phenyl)propanoic acid) is one of the most commonly prescribed and is a nonselective inhibitor of both COX-1
and COX-2,\(^7\) with a prominent analgesic and antipyretic role.\(^8\) It works by inhibiting cyclooxygenases and enzymes that are involved in the synthesis of prostaglandins that affects pain, inflammation, and fever.\(^9\) However, its short elimination half-life (~2 hours) and high degree of plasma protein binding (90%–99%)\(^10\) require it to be administered regularly.\(^11\) Naproxen (NAP; 2-(6-methoxynaphthalen-2-yl)propanoic acid) is another commonly prescribed NSAID used for the alleviation of moderate to severe pains, fever, and inflammation, including stiffness caused by osteoarthritis, rheumatoid arthritis, psoriatic arthritis, and ocular inflammations.\(^12\) It is a nonselective COX inhibitor and a potent inhibitor of prostaglandin synthesis.\(^13\) However, its low water solubility often translates to poor bioavailability. Celecoxib (CEL; 4-(5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide), another NSAID, is a selective COX-2 inhibitor that effectively modulates inflammation and pain. CEL is used for the treatment of pain, osteoarthritis, rheumatoid arthritis, primary dysmenorrhea, and ankylosing spondylitis.\(^14\) However, it also suffers from low bioavailability due to its large volume distribution (455±166 L), fast renal clearance (14.28 L/h), and high plasma protein binding (~97%).\(^15\) Currently, regular dosing of these drugs is required to reap the therapeutic benefits of noncontrolled-release NSAIDs. However, long-term usage of these NSAIDs is not recommended as they are known to cause adverse gastrointestinal side effects. These lead to a strong demand for controlled-release anti-inflammatory therapeutics that promise fewer side effects and better efficacy.

Drug delivery systems have become an important aspect of pharmaceutical reformulation, whereby off-patent drugs can enjoy an extension of their patentability through a newly formulated controlled-release version. Although conventional drug delivery systems encapsulate and deliver only a single drug,\(^16,17\) delivery systems that encapsulate multiple drug analogues or target drugs into specific tissues\(^18\) are conceivably more potent and effective. Such multi-drug delivery systems would be best suited for chronic diseases such as cancer, Parkinson’s disease, inflammatory diseases, and HIV, which require the simultaneous use of different drugs.\(^19,21\) The encapsulation of complementary drugs, with controlled release, would, therefore, allow for reduced drug dosages, thus reducing side effects while improving patient compliance and treatment efficacy.

The objective of this work was, therefore, to design a drug delivery system that allows for controlled and sustained release of NSAIDs. Here, we first report on the encapsulation of three different NSAIDs (ie, IBU, NAP, and CEL – as model drugs) into nanocarriers that are housed within a polymeric microcapsule (Scheme 1). The idea of first encapsulating drugs into polymeric nanocarriers is to avoid any potential drug–drug interactions. These polymers are the US Food and Drug Administration-approved, biocompatible, and biodegradable polymers – poly(l-lactide)
(PLLA) poly(caprolactone) (PCL), and poly(Ɛ,L-lactide-co- 
glycolide) (PLGA). Because NSAIDs are known to cause 
gastrointestinal problems, antacids are usually co-prescribed 
with these. Cimetidine (CIM), an antacid, is a histamine 
H2-receptor antagonist and is widely used to inhibit gastric 
juice secretion. Next, a modified version of the microcap-
sules that co-encapsulate NSAIDs (ie, IBU and NAP) and a 
histamine H2-receptor antagonist (ie, CIM) was developed, 
and its release capabilities were investigated. In essence, the 
development of such controlled-release delivery systems, 
with or without an antacid, aims at resolving the issues faced 
with the chronic use of NSAIDs.

Materials and methods

Materials

PLLA (IV: 2.4) and PLGA (50:50) (IV: 1.18) were pur-
chased from Corbion (the Netherlands). HCl solution (37% 
v/v Fuming), PCL (MW 10 kDa), IBU, NAP, CEL, CIM, 
Tween 20, Tween 80, Span 80, and polyvinyl alcohol (PVA) 
(MW 30–70 kDa) were purchased from Sigma-Aldrich 
(Steinheim, Switzerland). Extra virgin grade olive oil was 
purchased from Pietro Coricelli. For preparation of simulated 
gastric fluid (SGF), HCl solution (0.1 M HCl) was added 
to 0.02% (w/v) of Tween 20. The simulated intestinal fluid 
(SIF) consisted of phosphate-buffered saline (pH 6.8) and 
0.02% (w/v) Tween 80.

Methods

PLGA and PLLA nanoparticles synthesis

Dye or NSAIDs-loaded PLGA and PLLA nanoparticles were 
fabricated by the solvent evaporation method. Dye (0.1% w/v) 
or NSAID (8% w/v) was added into PLGA or PLLA/dichlo-
romethane (DCM) (0.2 g in 1 mL) solution. The resultant 
solution was mixed with 2% (w/v) PVA solution (2 mL) and 
ultrasonicated for a minute with ice. The primary emulsion 
was then transferred into distilled water (5 mL) under stirring 
at 400 rpm for 4 h. Next, the nanoparticle solution was washed 
with water followed by centrifugation (20,000 rpm, 10 min).

Preparing microcapsules encapsulating PLGA and 
PLLA nanoparticles

PLGA nanoparticles (0.1 g) and PLLA nanoparticles (0.1 g) 
were dispersed in 0.2% (w/v) Span 80 solution (1 mL) under 
ultrasonication. The aqueous suspension was added drop-
wise into PLGA or PLGA/PCL (1:1, w/w) DCM solution 
(5% w/v), containing CEL or CIM, under stirring (1,000 rpm, 
5 min). Next, the solution was added to 0.5% (w/v) PVA solu-
tion (250 mL) and emulsified at 400 rpm using an overhead 
stirrer for 4 h. The solution was washed using distilled water 
and freeze-dried. For the microcapsules containing CIM, 
olive oil (10 µL) was also added to the 0.2% (w/v) Span 80 
solution (1 mL) to achieve floatable microcapsules.

Encapsulation efficiency

To measure encapsulation efficiency, the microcapsules 
(10 mg) were solubilized in DCM (1 mL). Subsequently, 
denitized water (10 mL) was added to the DCM solution. The 
hydrophilic CIM partitions into distilled water and the super-
natant was injected into high-performance liquid chromatog-
raphy (HPLC) (Agilent 1100; Agilent Technologies, Santa 
Clara, CA, USA) with an autosampler and UV detector. The 
mobile phase was a mixture of acetonitrile and 0.1 M sodium 
acetate buffer (pH 5.0) (20:80 v/v) with the wavelength set 
at 230 nm. For hydrophobic IBU, NAP, and CEL, the drugs 
were redissolved in n-hexane to precipitate the polymer. The 
filtered supernatant was injected into HPLC with a mobile 
phase consisting of 1.8 mM phosphoric acid (pH 2.8) and 
acetonitrile (50:50, v/v). Encapsulation efficiency (EE) was 
calculated as follows:

\[
EE(\%) = \frac{\text{Weight of the drug in microcapsules}}{\text{Weight of total drug used}} \times 100\%
\]

Particle characterization with confocal laser 
microscopy and field-emission scanning electron 
microscopy

To determine dye distribution within the microcapsules, a 
confocal laser microscope (CLMS, LSM710) was used. Few 
droplets of the aqueous microcapsule suspension were placed 
onto a glass slide and the slide was sealed with a glass cover 
slip. The images were taken with a 63x/1.40 oil objective 
and the AxioCam MRm camera (Carl Zeiss Microscopy 
GmbH, Oberkochen, Germany). Further analysis of the 
photos was carried out using ZEN 2012 software (Carl Zeiss, 
Microscopy GmbH). To prepare the microcapsules for 
field-emission scanning electron microscopy (FESEM), 
microcapsules were placed on carbon tape-attached metal 
stub and cut using a blade, before coating with platinum.

Drug-release and polymer degradation studies

For drug-release study, microcapsules (10 mg) were added to 
SGF (20 mL) in glass vials under stirring at 37°C (200 rpm). 
Release medium (10 mL) was withdrawn at specific time points 
and replenished with fresh medium (10 mL). The amount of 
released drug was analyzed using HPLC, as described earlier. 
For polymer degradation study, microcapsules (50 mg) were 
dispersed in SGF (20 mL) and the solution was incubated under 
stirring and maintained at 37°C. Microcapsules were removed
at different time points. Size-exclusion chromatography (SEC) was used to measure the average molecular weight of PLGA with a reflective index detector. The flow rate was 1 mL/min. Since only PLGA is soluble in tetrahydrofuran, the polymers were separated using previously reported method.\(^{23}\) Subsequently, the polymers were dissolved individually into chloroform for SEC characterization.

Buoyancy and kinetics release profile
To determine the buoyancy of the microcapsules, the microcapsules were introduced to SGF (30 mL) under stirring for 24 h (200 rpm, 37°C). At different pre-determined time points, the numbers of microcapsules that remained afloat were visually counted. The percentage of floating microcapsules after 24 h was calculated based on the number of floating microcapsules over the total number of microcapsules initially used for this study. To analyze the rate of release, the release data were fitted to zero-order rate, first-order rate, Higuchi rate, and Korsmeyer–Peppas equations.\(^{25–27}\)

For statistical analysis, the Student’s \(t\)-test was used, and \(P<0.05\) was taken as statistically significant. Experimental data were obtained from three sample groups (\(n=3\)) and presented as mean ± SD.

Results and discussion
NSAIDs-loaded microcapsules
NSAIDs co-loaded microcapsules were fabricated using the solid/water/oil/water (S/W/O/W) emulsion solvent evaporation method. First, NSAIDs were loaded into polymeric nanoparticles and then encapsulated into larger hollow microcapsules (Scheme 1). This design allows for different drugs to be housed within different “compartments” (ie, nanoparticles) of the microcapsule thereby avoiding drug–drug interactions. For example, two different drugs can be loaded into PLGA and/or PLLA nanoparticles before encapsulating them within the microcapsule. Here, Span 80 plays an important role in this nanoencapsulation in the initial water-in-oil emulsion (W/O) system.\(^{29,30}\) First of all, PLGA microcapsules without Span 80 did not form any hollow cavity (Figure S2). Span 80 has a hydrophilic–lipophilic balance (HLB) of 4.3, which was suitable for stabilizing W/O emulsions. It allowed for the formation of small aqueous droplets (\(W_1\)) that contain the PLGA and PLLA nanoparticles, thus protecting these nanoparticles from dissolving in the organic solvent (DCM) in the external oil (O) phase. At the end, a hollow microcapsule containing drug-loaded nanoparticles was obtained. Comparing different shell materials, that is, PLGA and PLGA/PCL microcapsules, the latter were observed to have nonuniform layer thickness (Figure 2D). This may be due to the phase separation of PCL and PLGA. As such, the blend of rubbery
PCL with PLGA formed a shell that was less dense and of nonuniform thickness.\textsuperscript{31}

Next, drug-release kinetics of the delivery systems were investigated. Figure 3 plots the release profiles of solid microparticles and hollow microcapsules that contain all three NSAIDs. Control solid PLGA microparticles, which do not have any nanoparticles, gave similar release profiles for all three NSAIDs for up to 16 days. On the other hand, a longer sustained release was observed from both PLGA microcapsules and PLGA/PCL microcapsules.
Figure 2 FESEM images of (A) IBU-loaded PLGA nanoparticles, (B) NAP-loaded PLLA nanoparticles, (C) cross-sectioned CEL-loaded PLGA microcapsules containing PLGA and PLLA nanoparticles, and (D) CEL-loaded PLGA/PCL microcapsule containing PLGA and PLLA nanoparticles. Subsequent magnifications show PLGA and PLLA nanoparticles within the hollow cavity of the microcapsule.

Abbreviations: CEL, celecoxib; FESEM, field emission scanning electronic microscopy; IBU, ibuprofen; NAP, naproxen; PCL, polycaprolactone; PLGA, poly(L-lactide-co-glycolide); PLLA, poly(L-lactide).

Figure 3 Release profiles of three NSAIDs from (A) control solid PLGA microparticles (without nanoparticles), (B) PLGA hollow microcapsules (with nanoparticles), and (C) PLGA/PCL hollow microcapsules (with nanoparticles) in PBS (pH 7.4) at 37°C for 30 days (n=3).

Abbreviations: CEL, celecoxib; IBU, ibuprofen; NAP, naproxen; NSAIDs, nonsteroidal anti-inflammatory drugs; PBS, phosphate buffered saline; PCL, polycaprolactone; PLGA, poly(L-lactide-co-glycolide).
Nano-encapsulating microcapsules to combat inflammatory diseases

(both containing nanoparticles). Therefore, encapsulating drugs first into nanoparticles allowed this sustained releasing capability. Drug-release rates were also influenced by whether the drugs were loaded into PLGA or PLLA nanoparticles. Release results show that NAP released much slower than the other drugs because of its encapsulation into PLLA nanoparticles—a more hydrophobic polymer. Comparing two different shell compositions (ie, PLGA vs PLGA/PCL), the use of PLGA/PCL as the microcapsule shell material provided faster release rates because of the associated higher water uptake of PCL that translates to a faster degradation of the polymer shell (Figure 4A and B). The faster degradation of PCL was also evident from the SEM images of the degrading PLGA microcapsules and PLGA/PCL microcapsules over time (Figure 4C). A more porous PLGA/PCL microcapsule would also accelerate drug diffusion, thus leading to a more rapid drug-release rate (Figure 4C).

The oral route is the most convenient and economical route for drug administration. In view of the possible gastrointestinal problems with the use of NSAIDs, antacids are usually prescribed together with NSAIDs. Notably, IBU and NAP, both nonselective COX inhibitors, can cause gastric side effects. To address these issues, we designed the delivery system to provide a rapid release of an antacid (ie, CIM), followed by a controlled and sustained release of NSAIDs (ie, IBU and NAP). Here, IBU and NAP were encapsulated within PLGA and PLLA nanoparticles, respectively, whereas CIM (in the place of CEL) was encapsulated in the shell of either PLGA or PLGA/PCL microcapsules. Loading efficiency of IBN and NAP in their respective nanoparticles was again 90%. However, CIM being hydrophilic in nature (log P = 0.11) had a lower encapsulation efficiency (~47%) in the shell of the microcapsules.

To increase oral bioavailability of drugs, these microcapsules should possess good buoyancy property, which allows for a prolonged gastric residence time (GRT) and for drugs to be released in the upper gastrointestinal tract.

The oral route is the most convenient and economical route for drug administration. In view of the possible gastrointestinal problems with the use of NSAIDs, antacids are usually prescribed together with NSAIDs. Notably, IBU and NAP, both nonselective COX inhibitors, can cause gastric side effects. To address these issues, we designed the delivery system to provide a rapid release of an antacid (ie, CIM), followed by a controlled and sustained release of NSAIDs (ie, IBU and NAP). Here, IBU and NAP were encapsulated within PLGA and PLLA nanoparticles, respectively, whereas CIM (in the place of CEL) was encapsulated in the shell of either PLGA or PLGA/PCL microcapsules. Loading efficiency of IBN and NAP in their respective nanoparticles was again >90%. However, CIM being hydrophilic in nature (log P = 0.11) had a lower encapsulation efficiency (~47%) in the shell of the microcapsules.

To increase oral bioavailability of drugs, these microcapsules should possess good buoyancy property, which allows for a prolonged gastric residence time (GRT) and for drugs to be released in the upper gastrointestinal tract.

For example, floating lipid beads showed better oral bioavailability (162.7%) of Cinnarizine as compared to non-floatable Stugeron®. In addition, Ofloxacin-loaded floating hollow microcapsules exhibited a higher oral bioavailability (124.1%) as compared to commercial Ofloxacin tablets. The buoyancy of the PLGA microcapsules and PLGA/PCL microcapsules is plotted in Figure 5. The results show that...
PLGA microcapsules possessed better floating capabilities compared to PLGA/PCL microcapsules. The excellent buoyancy of the former was due to its low density, attributed to the oil-filled hollow cavity, along with the hydrophobic nature of PLGA that restricted water influx into the microcapsules. PLGA microcapsules exhibited 88% of the microcapsules floating at 24 h, whereas PLGA/PCL microcapsules had only 42% of microcapsules floating at 24 h. For this reason, the PLGA microcapsules were chosen for further studies.

As floating microspheres had been reported to achieve a prolonged GRT (5 h) in humans, the release study was conducted under the same conditions that would mimic drug dissolution in the upper gastrointestinal tract (in SGF for 5 h), followed by release in the intestinal tract (in SIF for remaining 19 h). Hence, the release studies were conducted in SGF (5 h) and SIF (24 h). Figure 6 plots the release profiles of the three drugs from the PLGA microcapsules. Since gastric discomfort is the main side effect of NSAIDs, the release of over 75% of CIM in the stomach within 5–7 h to combat this would be advantageous. As shown in Figure 6, the microcapsules exhibited sequential release of the drugs (first CIM, followed by NSAIDs) in SGF and SIF over 24 h. Notably, the release profile of the microcapsules indicated that small amounts of NSAIDs would be released into the stomach according to the gastric residence period, and the rest would be released into the intestine. CIM release was observed to be the fastest, while the encapsulation of two NSAIDs within PLGA and PLLA nanoparticles achieved a delayed and more sustained release profile.

This formulation could now achieve sequential release of two NSAIDs and an antacid for oral delivery. This delivery system could modulate release kinetics of drugs regardless of their hydrophobic nature. To explain the mechanism of release profiles of these drugs from the formulations, the release results were fitted to the following models: Higuchi’s equation and Korsmeyer–Peppas equation. Table 1 summarizes the $r^2$ coefficient values of all the three drugs and their respective rate constants from these models.

Higuchi’s equation fits well for IBU and NAP, indicating the drug-release mechanism was diffusion controlled. In addition, the $n$ values of Korsmeyer–Peppas for IBU and NAP were $<0.5$, indicating the Fickian diffusion mechanism. The release of these two drugs from nanoparticles through the microcapsule likely mimics that of a drug-loaded matrix. However, the Korsmeyer–Peppas equation predicted an $n$ value of 0.81 for hydrophilic CIM that is housed within the PLGA shell of these microcapsules. This $n$ value indicates a non-Fickian diffusion that refers to combination of both diffusion and erosion controlled rate release. It was reported that the decrease in average molecular weight of PLGA microparticles followed first-order degradation kinetics for both acidic and basic conditions. Specifically, at acidic pH (ie, SGF), faster degradation and release of drug would occur due to the crystallization of oligomeric degradation products at acidic pH. Hence, CIM can be released from the microcapsule shell through both diffusion and extensive degradation of the capsule shell (Figure 4). This oral formulation for

**Table 1** Correlation coefficient and release rate constants of CIM, IBU, and NAP from PLGA microcapsules after fitting to the various release rate equations

<table>
<thead>
<tr>
<th>Drug</th>
<th>Correlation coefficient ($r^2$)</th>
<th>Rate constant/n value</th>
</tr>
</thead>
<tbody>
<tr>
<td>CIM</td>
<td>Higuchi: 0.6919, Korsmeyer–Peppas: 0.9879</td>
<td>Higuchi: K (h$^{-1}$), Korsmeyer–Peppas, n value</td>
</tr>
<tr>
<td>IBU</td>
<td>0.9889</td>
<td>11.947, 0.41</td>
</tr>
<tr>
<td>NAP</td>
<td>0.9474</td>
<td>7.472, 0.44</td>
</tr>
</tbody>
</table>

Abbreviations: CIM, cimetidine; IBU, ibuprofen; NAP, naproxen; PLGA, poly(3,3-lactide-co-glycolide).
controlled and sustained release of an antacid with NSAIDs would provide benefits of the latter while protecting the stomach from gastrointestinal side effects.

The usage of complementary drugs for the treatment of diseases is now gaining traction in the pharmaceutical industry. For instance, for Parkinson’s disease, patients would require administration of three drugs to manage this neurological disease. At the same time, there have been recent advances in complementary therapy of drugs with nutraceuticals in combating gastrointestinal illnesses. Complementary delivery, therefore, synergizes drugs of different mechanisms of action by co-encapsulating them into delivery systems. This study, therefore, proves the ability of delivering complementary drugs through the careful design of an oral delivery system. Although this study provides knowledge on the feasibility of delivering drugs, that is, an antacid with NSAIDs, from a single delivery system, its limitation lies in the need to further evaluate its effectiveness through more realistic animal models. In addition, large-scale manufacturing of the microcapsules has not been explored, although this simple, economical, and single-step fabrication process may be an attractive approach. Therefore, part of the future plan for this delivery system is to scale up this fabrication process and to evaluate its efficacy through relevant in vivo tests.

**Conclusion**

In this article, nanoencapsulated microcapsules were designed to deliver NSAIDs. The drug-release results showed that a more sustained release of IBU and NAP were observed when they were pre-loaded into PLGA and PLLA nanoparticles, before encapsulating them into larger hollow PLGA and PLGA/PCL microcapsules. These microcapsules exhibited sustained release of NSAIDs in phosphate-buffered saline beyond 30 days. Next, CIM (an antacid) was co-loaded with the NSAIDs, and a sequential release of CIM followed by NSAIDs in SGF was observed. CIM, which was loaded into the shell of the microcapsules, had a more rapid and immediate release, followed by a delayed and sustained release of the NSAIDs. This floating delivery system could, therefore, be a promising platform to control the delivery of NSAIDs to combat inflammatory diseases while protecting against possible gastrointestinal side effects that may arise from the overuse of NSAIDs.

**Acknowledgments**

This work was made possible through the financial support of the School of Materials Science and Engineering (M020070110), the Nanyang Technological University-National Healthcare Group (ARG/14012), the Ministry of Education (RG11/16), and the Singapore Centre on Environmental Life Sciences Engineering (M4330001.C70.703012).

**Disclosure**

The authors report no conflicts of interest in this work.

**References**

Supplementary materials

Figure S1 DLS results of (A) PLGA nanoparticles and (B) PLLA nanoparticles.
Abbreviations: DLS, dynamic light scattering; PLGA, poly(D,L-lactide-co-glycolide); PLLA, poly(L-lactide).

Figure S2 Cross-sectioned PLGA microcapsules without Span 80 loaded PLGA and PLLA nanoparticles.
Abbreviation: PLGA, poly(D,L-lactide-co-glycolide).